Rexahn Pharmaceuticals has announced the appointment of Douglas J. Swirsky as its president and chief financial officer.    Mr. Swirsky was most recently president, chief executive officer, and a director of GenVec, Inc., a publicly-traded biotechnology company. He is on the board of directors of Fibrocell Science, Inc., Cellectar Biosciences, Inc., and Pernix Therapeutics Holdings, Inc.     “Doug’s extensive leadership, corporate finance and strategy experience make him a strong...